Veracyte traded at $41.25 this Friday August 14th, decreasing $1.35 or 3.17 percent since the previous trading session. Looking back, over the last four weeks, Veracyte lost 30.68 percent. Over the last 12 months, its price rose by 36.50 percent. Looking ahead, we forecast Veracyte to be priced at 40.36 by the end of this quarter and at 37.82 in one year, according to Trading Economics global macro models projections and analysts expectations.
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.